Question marks because we don't know who the other nominees will be, though I am assuming that Pourhassan and Kelly will be on the Proxy Card.
The next CYDY BoDs, whoever they are, will have a huge challenge with recapitalization and assuring that the Clinical Research Process is on solid footing with the FDA. The Board will need the support of shareholders to stabilize the SP and secure the confidence of a legitimate sources of non-toxic financing. Let's keep this in mind as we move through the Proxy Solicitation Period in August and September.